Under construction – not a live service

Skip to content

Frontlight Research

Institution

Beth Israel Deaconess Medical Center

Boston, United StatesWebsite

Also known as: BIDMC

458running trials
177closed trials
91,125publications (OpenAlex)

Running trials

Not yet recruiting
Gastrointestinal Dopamine Decarboxylase and Levodopa Pharmacokinetics
NCT07793461· Phase 4· Beth Israel Deaconess Medical Center· Source
Not yet recruiting
Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer
NCT07925333· Phase 2· Beth Israel Deaconess Medical Center· Source
Not yet recruiting
The CARDIOPROTECT Trial
NCT07654426· Phase 2· Beth Israel Deaconess Medical Center· Source
Not yet recruiting
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
NCT07728188· Phase 3· AbbVie· Source
Not yet recruiting
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
NCT07850063· Phase 3· Boehringer Ingelheim· Source
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
NCT07806149· National Heart, Lung, and Blood Institute (NHLBI)· Source
Not yet recruiting
A Clinical Study to Evaluate the Safety and Immunogenicity of a Higher Dose of the Study Vaccine, VIR-1388, in HCMV-seropositive Adult Participants Without HIV
NCT07801456· Phase 1· National Institute of Allergy and Infectious Diseases (NIAID)· Source
Not yet recruiting
Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis
NCT07755059· Massachusetts General Hospital· Source
Not yet recruiting
A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.
NCT06458907· P+F Products + Features USA Inc.· Source
Not yet recruiting
Cilostazol for Prevention of Recurrent Stroke Trial
NCT07174414· Phase 3· Stanford University· Source
Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200· Phase 3· Incyte Corporation· Source
Not yet recruiting
Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma
NCT07601100· Phase 1/2· Dana-Farber Cancer Institute· Source
Recruiting
The Safety and Efficacy of Roflumilast Foam in HS
NCT07263230· Phase 2· Beth Israel Deaconess Medical Center· Source
Recruiting
D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM
NCT07624513· Phase 3· Dana-Farber Cancer Institute· Source
Recruiting
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
NCT06996652· Phase 2· Yale University· Source
Recruiting
RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer
NCT07735624· Phase 2· Dana-Farber Cancer Institute· Source
Not yet recruiting
ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
NCT07247097· Phase 2· Massachusetts General Hospital· Source
Enrolling by invitation
Effect of PEEP on Cardiac Function
NCT07531602· Beth Israel Deaconess Medical Center· Source
Enrolling by invitation
Six Versus Twelve Month Index Follow-up After Large Colon Polyp Resection
NCT07198945· Indiana University· Source
Not yet recruiting
PRISM-NLM: Prostatectomy Intraoperative Surgical Margin Assessment With Non-linear Microscopy
NCT07516808· Beth Israel Deaconess Medical Center· Source
Recruiting
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
NCT07527858· Phase 2· Gilead Sciences· Source
Recruiting
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
NCT07326566· Phase 2· Black Diamond Therapeutics, Inc.· Source
Recruiting
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
NCT07405190· Phase 2· Massachusetts General Hospital· Source
Recruiting
Horizon Two: HR NDMM (MMRC-100)
NCT07053436· Phase 2· Multiple Myeloma Research Consortium· Source
Recruiting
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
NCT07321652· Phase 3· Alliance for Clinical Trials in Oncology· Source
Recruiting
Mechanisms Of Orbitofrontal Stimulation in Depression
NCT07230990· Subha Subramanian· Source
Recruiting
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
NCT07489495· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation
NCT07523750· Biosense Webster, Inc.· Source
Recruiting
A Multi Center Study Testing a New Implant for Adults With Severe Emphysema
NCT07119229· Pulmair Medical, Inc.· Source
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
NCT07326709· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
NCT07397611· Phase 2· Dana-Farber Cancer Institute· Source
Recruiting
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
NCT07410117· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
NCT07432958· Phase 2· Appello Pharmaceuticals, Inc.· Source
Active, not recruiting
Intravascular Neuro OCT Imaging System for Aneurysm Treatment Evaluation
NCT07214220· Spryte Medical· Source
Recruiting
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT07284758· Phase 2· C4 Therapeutics, Inc.· Source
Recruiting
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
NCT07374029· Phase 1· David Avigan· Source
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
NCT07377435· Phase 1· David Avigan· Source
Active, not recruiting
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
NCT07244263· Phase 2· Takeda· Source
Recruiting
A Study of Isoquercetin in People With Ovarian Cancer
NCT07303894· Phase 2· Memorial Sloan Kettering Cancer Center· Source
Recruiting
Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease
NCT07378644· Phase 2/3· Skyhawk Therapeutics, Inc.· Source
Recruiting
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
NCT07384975· Phase 2· Navigator Medicines, Inc.· Source
Recruiting
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
NCT07104565· Phase 2· Incyte Corporation· Source
Recruiting
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07225569· Phase 2· Sanofi· Source
Recruiting
Diagnosing Epilepsy To EffeCT Change
NCT07110337· Epiminder America, Inc.· Source
Recruiting
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
NCT07110454· Epiminder America, Inc.· Source
Recruiting
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
NCT06861088· Phase 3· Quercis Pharma AG· Source
Recruiting
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
NCT07032714· Phase 1· Massachusetts General Hospital· Source
Active, not recruiting
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037· Phase 2· Vertex Pharmaceuticals Incorporated· Source
Recruiting
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT07061977· Phase 3· National Cancer Institute (NCI)· Source

Showing 50 of 458.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Multiple myeloma18 recruiting
Lung cancer16 recruiting
Ovarian cancer12 recruiting
Coronary artery disease11 recruiting
Pancreatic cancer9 recruiting
Prostate cancer9 recruiting
Aortic aneurysm8 recruiting
Acute myeloid leukaemia7 recruiting
Parkinson disease7 recruiting
Chronic lymphocytic leukaemia6 recruiting
Diffuse large B-cell lymphoma6 recruiting
Head and neck cancer6 recruiting
High blood pressure6 recruiting
Triple-negative breast cancer6 recruiting
Childhood cancers5 recruiting
COPD5 recruiting
Follicular lymphoma5 recruiting
Gastric and oesophageal cancer5 recruiting
Heart failure5 recruiting
Cervical cancer4 recruiting
Colorectal cancer4 recruiting
Endometrial cancer4 recruiting
Huntington's disease4 recruiting
Kidney cancer4 recruiting
Liver and biliary tract cancer4 recruiting
Myeloproliferative neoplasms4 recruiting
Stroke4 recruiting
Atrial fibrillation3 recruiting
Bipolar disorder3 recruiting
Bladder cancer3 recruiting
Depression3 recruiting
Epilepsy3 recruiting
Hidradenitis suppurativa3 recruiting
Immune thrombocytopenia (ITP)3 recruiting
Mantle cell lymphoma3 recruiting
Melanoma3 recruiting
Metastatic breast cancer3 recruiting
Schizophrenia3 recruiting
Ventricular tachycardia3 recruiting
ALS (motor neurone disease)2 recruiting
Alzheimer disease2 recruiting
Glioblastoma2 recruiting
Hodgkin lymphoma2 recruiting
Insomnia2 recruiting
Myasthenia gravis2 recruiting
Myelodysplastic syndromes2 recruiting
Obesity2 recruiting
Acute lymphoblastic leukaemia1 recruiting
Barrett's oesophagus1 recruiting
Brain aneurysm1 recruiting
Chronic kidney disease1 recruiting
Chronic myeloid leukaemia1 recruiting
CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
Coeliac disease1 recruiting
Dermatomyositis and polymyositis (myositis)1 recruiting
Fatty liver disease (MASLD/MASH)1 recruiting
Frontotemporal dementia1 recruiting
HIV1 recruiting
Hypertrophic cardiomyopathy1 recruiting
Lewy body dementia1 recruiting
Liver cirrhosis1 recruiting
Long COVID and ME/CFS1 recruiting
Meningioma1 recruiting
Migraine1 recruiting
Multiple sclerosis1 recruiting
Multiple system atrophy1 recruiting
Myocarditis1 recruiting
Obstructive sleep apnoea1 recruiting
Peripheral artery disease1 recruiting
Polycystic kidney disease1 recruiting
Primary biliary cholangitis1 recruiting
Sarcoma1 recruiting

Closed trials

Completed
A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:
NCT06676072· Abbott Medical Devices· Source
Completed
Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)
NCT06593600· Phase 2· Regeneron Pharmaceuticals· Source
Completed
ADVENT Trial Long Term Outcomes Evaluating Atrial Fibrillation Progression Study
NCT06526546· Boston Scientific Corporation· Source
Completed
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
NCT06667414· Hoffmann-La Roche· Source
Completed
Online Tai Chi Plus Fitbit After ACS
NCT05699642· Phase 2· Beth Israel Deaconess Medical Center· Source
Completed
RECOVER-SLEEP: Platform Protocol
NCT06404086· Phase 2· Duke University· Source
Completed
RECOVER-ENERGIZE Platform Protocol
NCT06404047· Duke University· Source
Terminated
To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate
NCT06488911· Phase 3· Intercept Pharmaceuticals· Source
Completed
VITALYST Early Feasibility Study in High-Risk PCI Patients (VITALYST EFS)
NCT06132568· Boston Scientific Corporation· Source
Recruiting
Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial
NCT05918263· Fred Hutchinson Cancer Center· Source
Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638· Orchestra BioMed, Inc· Source
Completed
A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease
NCT06001177· Phase 2· Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA· Source
Terminated
Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).
NCT05997277· Phase 2· Beth Israel Deaconess Medical Center· Source
Completed
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864· Phase 3· Boehringer Ingelheim· Source
Terminated
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
NCT05983133· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source
Completed
Brief Cognitive Behavioral Therapy to Enhance Benzodiazepine Deprescribing
NCT06119308· Beth Israel Deaconess Medical Center· Source
Terminated
Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06118099· Phase 2· Sanofi· Source
Completed
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06046729· Phase 2· Eli Lilly and Company· Source
Terminated
Visualization of the STN and GPi for DBS
NCT05774041· Surgical Information Sciences Inc.· Source
Terminated
A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06028230· Phase 2· Sanofi· Source
Completed
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT05848011· Phase 2· MacroGenics· Source
Completed
Early Parkinson's Disease Monotherapy With CVN424
NCT06006247· Phase 2· Cerevance Beta, Inc.· Source
Completed
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
NCT06060665· Phase 3· Gilead Sciences· Source
Completed
RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms
NCT05595369· Phase 2· Kanecia Obie Zimmerman· Source
Completed
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
NCT05814627· Phase 3· AbbVie· Source
Withdrawn
Define Predictors of Response to Ozanimod in UC Discovering Biomarkers in the Management of Ulcerative Colitis
NCT05809583· Beth Israel Deaconess Medical Center· Source
Completed
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
NCT05819359· Phase 2· Bial R&D Investments, S.A.· Source
Completed
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
NCT05630183· Phase 2· Agenus Inc.· Source
Terminated
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
NCT05827614· Phase 1· Boundless Bio, Inc.· Source
Terminated
The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.
NCT05696392· Phase 4· Incyte Corporation· Source
Terminated
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NCT05787496· Phase 1· NextCure, Inc.· Source
Completed
NHLBI Transmural Electrosurgery LeafLet Traversal And Laceration Evaluation (TELLTALE) BASILICA-TAVR Trial
NCT05666713· National Heart, Lung, and Blood Institute (NHLBI)· Source
Completed
A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
NCT05656911· Phase 2· Bayer· Source
Completed
A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
NCT05526248· Phase 2· Bayer· Source
Completed
Causal Lesion Network Guided Treatment of Bipolar Mania With Transcranial Electrical Stimulation
NCT05445466· Beth Israel Deaconess Medical Center· Source
Completed
Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
NCT05635838· Phase 2· Incyte Corporation· Source
Completed
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05601882· Phase 3· AbbVie· Source
Completed
Yoga for Mental Health in Parkinson's Patients
NCT05335850· Beth Israel Deaconess Medical Center· Source
Completed
Groceries for Black Residents of Boston to Stop Hypertension Among Adults With Treated Hypertension
NCT05393232· Beth Israel Deaconess Medical Center· Source
Completed
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
NCT05121337· Beth Israel Deaconess Medical Center· Source
Completed
What the Nose Knows: Hedonic Capacity, Psychosocial Interventions and Outcomes in Schizophrenia
NCT05282186· Beth Israel Deaconess Medical Center· Source
Completed
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet
NCT05353985· Phase 2· Takeda· Source
Completed
Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet
NCT04530123· Phase 2· Takeda· Source
Terminated
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
NCT05130866· Phase 2/3· Recursion Pharmaceuticals Inc.· Source
Terminated
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
NCT05310071· Phase 3· Biogen· Source
Completed
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
NCT05348785· Phase 2· Biogen· Source
Completed
Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults
NCT04983030· Phase 1/2· Boris Juelg, MD PhD· Source
Completed
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
NCT05216263· Phase 3· AbbVie· Source
Terminated
Sodium Nitroprusside in Early Course Schizophrenia
NCT04986072· Phase 2· Beth Israel Deaconess Medical Center· Source
Completed
Esophageal Protection Study: A Multicenter Study
NCT04577859· Advanced Cooling Therapy LLC, d/b/a Attune Medical· Source

Showing 50 of 177.

Registry name variants (73)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Beth Israel Deaconess Medical Center
Boston, Massachusetts 02215
509 trials
Beth Israel Deaconess Medical Center/Winchester Center for Cancer Care
Winchester, Massachusetts 01890
32 trials
Beth Israel Deaconess Medical Center (BIDMC)
Boston, Massachusetts 02215
22 trials
Beth Israel Deaconess Med Ctr
Boston, Massachusetts 02215
7 trials
Beth Israel Deaconess Med Center
Boston, Massachusetts 02215
5 trials
Beth Israel Deaconess Medical Center, Inc.
Boston, Massachusetts 02215
4 trials
Beth Israel Deaconess Medical Center, Harvard Medical School
Boston, Massachusetts 02215
3 trials
- NCT04619004HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
- NCT02818972RelayPro Thoracic Stent-Graft in Subjects With Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers
- NCT00756665Prostate Active Surveillance Study
  Contact: Gabriela NietoBlanco
Beth Israel Deaconess Medical Center - 330 Brookline Ave
Boston, Massachusetts 02115
2 trials
- NCT04129502TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- NCT03301506Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
Beth Israel Deaconess Medical Center - Arnold Pain Management
Brookline, Massachusetts 02115
2 trials
- NCT06047444A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
- NCT06047457A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
Beth Israel Deaconess Medical Center - Clinical Research Center
Boston, Massachusetts 02215
2 trials
- NCT05393232Groceries for Black Residents of Boston to Stop Hypertension Among Adults With Treated Hypertension
- NCT05121337Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
Beth Israel Deaconess Medical Center - Nephrology
Boston, Massachusetts 02215
2 trials
- NCT07161037Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
- NCT06747572Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
Beth Israel Deaconess Medical Centre
Boston, Massachusetts 02115
2 trials
- NCT05335850Yoga for Mental Health in Parkinson's Patients
- NCT05139979Yogic Breathing and Guided Meditation for Long Covid Symptoms
8400998 - Beth Israel Deaconess Medical Center
Boston, Massachusetts 02215
1 trial
- NCT03473223Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
Beth Israel Deaconess Medical Center - 110 Francis St- Site Number : 8400013
Boston, Massachusetts 02215-5563
1 trial
- NCT06028230A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Beth Israel Deaconess Medical Center / BIDMC VCRS (Site #32077)
Boston, Massachusetts 02215
1 trial
- NCT07801456A Clinical Study to Evaluate the Safety and Immunogenicity of a Higher Dose of the Study Vaccine, VIR-1388, in HCMV-seropositive Adult Participants Without HIV
Beth Israel Deaconess Medical Center - Boston- Site Number : 8400001
Boston, Massachusetts 02215
1 trial
- NCT07225569A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Beth Israel Deaconess Medical Center - Boston- Site Number : 8400005
Boston, Massachusetts 02215
1 trial
- NCT06356571A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Beth Israel Deaconess Medical Center - Boston- Site Number : 8401041
Boston, Massachusetts 02215
1 trial
- NCT06141473Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Beth Israel Deaconess Medical Center (Data Collection Only)
Boston, Massachusetts 02215
1 trial
- NCT07303894A Study of Isoquercetin in People With Ovarian Cancer
  Contact: Robert Flaumenhaft, MD, PhD
Beth Israel Deaconess Medical Center - Dermatology
Boston, Massachusetts 02115
1 trial
- NCT05656911A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
Beth Israel Deaconess Medical Center - Division of Hematology/Oncology
Boston, Massachusetts 02215
1 trial
- NCT06850623Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
  Contact: Selma Sinanovic Study Coordinator
Beth Israel Deaconess Medical Center/East
Boston, Massachusetts 02215
1 trial
- NCT03915951An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Beth Israel Deaconess Medical Center,East Campus Research Pharmacy
Boston, Massachusetts 02215
1 trial
- NCT04389632A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Beth Israel Deaconess Medical Center /ID# 200545
Boston, Massachusetts 02215-5400
1 trial
- NCT03568318A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Beth Israel Deaconess Medical Center /ID# 201155
Boston, Massachusetts 02215-5400
1 trial
- NCT02993523A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
Beth Israel Deaconess Medical Center /ID# 208124
Boston, Massachusetts 02215-5400
1 trial
- NCT03539536Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Beth Israel Deaconess Medical Center /ID# 210904
Boston, Massachusetts 02215-5400
1 trial
- NCT03314181A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
Beth Israel Deaconess Medical Center /ID# 218149
Boston, Massachusetts 02215-5400
1 trial
- NCT04295538Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)
Beth Israel Deaconess Medical Center /ID# 222505
Boston, Massachusetts 02215-5400
1 trial
- NCT04451772A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State
Beth Israel Deaconess Medical Center /ID# 224261
Boston, Massachusetts 02215-5400
1 trial
- NCT04472598Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
Beth Israel Deaconess Medical Center /ID# 225069
Boston, Massachusetts 02215-5400
1 trial
- NCT04401748Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
Beth Israel Deaconess Medical Center /ID# 228094
Boston, Massachusetts 02215-5400
1 trial
- NCT04524611Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
Beth Israel Deaconess Medical Center /ID# 228214
Boston, Massachusetts 02215-5400
1 trial
- NCT04686136A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
Beth Israel Deaconess Medical Center /ID# 240683
Boston, Massachusetts 02215-5400
1 trial
- NCT05139602A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy
Beth Israel Deaconess Medical Center /ID# 241800
Boston, Massachusetts 02215-5400
1 trial
- NCT05216263Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
Beth Israel Deaconess Medical Center /ID# 248651
Boston, Massachusetts 02215-5400
1 trial
- NCT05451810A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
Beth Israel Deaconess Medical Center /ID# 249302
Boston, Massachusetts 02215-5400
1 trial
- NCT05753501Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
Beth Israel Deaconess Medical Center /ID# 251212
Boston, Massachusetts 02215-5400
1 trial
- NCT05601882A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Beth Israel Deaconess Medical Center /ID# 252009
Boston, Massachusetts 02215-5400
1 trial
- NCT04777994Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
  Contact: Nicole Director Clinical Operations
Beth Israel Deaconess Medical Center /ID# 253811
Boston, Massachusetts 02215-5400
1 trial
- NCT05889182A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Beth Israel Deaconess Medical Center /ID# 263703
Boston, Massachusetts 02215
1 trial
- NCT06389136A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
Beth Israel Deaconess Medical Center /ID# 263709
Boston, Massachusetts 02215
1 trial
- NCT06468228A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Beth Israel Deaconess Medical Center /ID# 271535
Boston, Massachusetts 02215
1 trial
- NCT06158841Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Beth Israel Deaconess Medical Center /ID# 285204
Boston, Massachusetts 02215
1 trial
- NCT07728188A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Beth Israel Deaconess Medical Center - Liver Center
Boston, Massachusetts 02215
1 trial
- NCT04849728A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
Beth Israel Deaconess Medical Center, Liver Research Center
Boston, Massachusetts 02215
1 trial
- NCT06447168A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
Beth Israel Deaconess Medical Center - Oncology
Boston, Massachusetts 02215
1 trial
- NCT05526248A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
Beth Israel Deaconess Medical Center - Rheumatology /ID# 255029
Boston, Massachusetts 02149-4903
1 trial
- NCT05814627Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Beth Israel Deaconess Medical Center (Site 0043)
Boston, Massachusetts 02215
1 trial
- NCT06925737A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
  Contact: Study Coordinator
Beth Israel Deaconess Medical Center (Site 0044)
Boston, Massachusetts 02215
1 trial
- NCT06956235Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
Beth Israel Deaconess Medical Center (Site 0070)
Boston, Massachusetts 02215
1 trial
- NCT03615326Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
Beth Israel Deaconess Medical Center (Site 0089)
Boston, Massachusetts 02215
1 trial
- NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Beth Israel Deaconess Medical Center (Site 0139)
Boston, Massachusetts 02215
1 trial
- NCT07489495A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
  Contact: Study Coordinator
Beth Israel Deaconess Medical Center (Site 0141)
Boston, Massachusetts 02215
1 trial
- NCT03553836Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
Beth Israel Deaconess Medical Center (Site 0161)
Boston, Massachusetts 02215
1 trial
- NCT06890884A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
  Contact: Study Coordinator
Beth Israel Deaconess Medical Center (Site 0716)
Boston, Massachusetts 02215
1 trial
- NCT03713593Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
Beth Israel Deaconess Medical Center (Site 1002)
Boston, Massachusetts 02215
1 trial
- NCT04846920A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)
Beth Israel Deaconess Medical Center (Site #: 1004)
Boston, Massachusetts 02215
1 trial
- NCT05217628An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.
Beth Israel Deaconess Medical Center (Site 1501)
Boston, Massachusetts 02215
1 trial
- NCT04195750A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Beth Israel Deaconess Medical Center (Site 1957)
Boston, Massachusetts 02215
1 trial
- NCT05933577A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Beth Israel Deaconess Medical Center (Site #211)
Boston, Massachusetts 02215-5400
1 trial
- NCT07432958A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
  Contact: Annie Blobaum, Ph.D.
Beth Israel Deaconess Medical Center - Site #337
Boston, Massachusetts 02215
1 trial
- NCT05248646Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
Beth Israel Deaconess Medical Center (Site ID: 32077)
Boston, Massachusetts 02215
1 trial
- NCT06557785A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV
Beth Israel Deaconess Medical Center- Site Number : 1099
Boston, Massachusetts 02215
1 trial
- NCT03395210A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)
Beth Israel Deaconess Medical Center Site Number : 8400006
Boston, Massachusetts 02215
1 trial
- NCT06118099Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Beth Israel Deaconess Medical Center Site Number: 8400019
Boston, Massachusetts 02215
1 trial
- NCT07007962Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Beth Israel Deaconess Medical Centre, Harvard Medical School
Boston, Massachusetts 02215
1 trial
- NCT04280029SELUTION SLR™ 014 In-stent Restenosis
Beth Israel Deaconess Medical Ctr. (Site 0033)
Boston, Massachusetts 02215
1 trial
- NCT03867084Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
Beth Israel Deaconess Medical Ctr. (Site 0044)
Boston, Massachusetts 02215
1 trial
- NCT03142334Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
Beth Israel Deaconess Medical Ctr. (Site 0093)
Boston, Massachusetts 02215
1 trial
- NCT03834519Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
Dana-Farber Cancer Institute / Beth Israel Deaconess Medical Center
Boston, Massachusetts 02115
1 trial
- NCT04812366Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
  Contact: Daniella Furtado
Harvard Medical School - Beth Israel Deaconess Medical Center (BIDMC) - West Campus
Boston, Massachusetts 02215-5321
1 trial
- NCT06706622A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
Beth Israel Deaconess Medical Center / BIDMC VCRS (Site ID: 32077)
Boston, Massachusetts 02115

Conditions

Diseases this institution publishes on or runs trials for.

Stroke265 works · 13 trials
Heart failure209 works · 12 trials
Obesity138 works · 7 trials
HIV113 works · 6 trials
Atrial fibrillation100 works · 12 trials
Type 2 diabetes97 works · 0 trials
Schizophrenia79 works · 10 trials
Liver and biliary tract cancer74 works · 22 trials
Prostate cancer66 works · 40 trials
Kidney cancer57 works · 24 trials
Coronary artery disease53 works · 20 trials
Parkinson disease52 works · 19 trials
Fatty liver disease (MASLD/MASH)50 works · 6 trials
Chronic kidney disease49 works · 3 trials
Hidradenitis suppurativa36 works · 16 trials
Epilepsy34 works · 4 trials
Obstructive sleep apnoea34 works · 2 trials
Migraine32 works · 5 trials
Insomnia30 works · 4 trials
Aortic aneurysm29 works · 11 trials
Ovarian cancer28 works · 29 trials
COPD28 works · 8 trials
Bladder cancer26 works · 6 trials
Aortic stenosis26 works · 6 trials
Multiple myeloma25 works · 42 trials
Osteoporosis25 works · 2 trials
Lupus (SLE)23 works · 1 trial
Coeliac disease22 works · 5 trials
Brain aneurysm22 works · 3 trials
Triple-negative breast cancer21 works · 19 trials

Institution data: ROR 04drvxt59 (CC0-1.0)Updated 12 Nov 2026

Report an error